Beyond gluten: the multifaceted regulation of MHC class II in celiac disease pathogenesis Authors: Nastaran Asri, Mohadeseh Mahmoudi Ghehsareh, Armina Assarin, Nooshin Miladi, Hamidreza Houri, Somayeh Jahani- Sherafat, Sajjad Tavakkoli, Nikoo Hossein-Khannazer, Mohammad Rostami-Nejad Published: 2025 ABSTRACT Celiac disease (CD) is a complex immune-mediated disorder influenced by genetic predispositio and environmental triggers, which human leukocyte antigen (HLA)-DQ2/8 playing a central role in disease pathogenesis. Gluten peptides deamidated by tissue transglutaminase 2 (tTG2) bind to CD4⁺ T cells via major histocompatibility complex (MHC) class II molecules, initiating an inflammatory cascade that damages the intestinal mucosa. Although many individuals carry HLA-DQ2/8 alleles, only a subset develops CD, suggesting the contribution of additional regulatory factors. This review examines the critical function of the MHC class II transactivator (CIITA) in regulating HLA-DQ expression through post-translational modifications, including phosphorylation, acetylation, and ubiquitination, and its interactions with histone acetyltransferases (HATs). We highlight how gliadin-induced mitogen-activated protein kinase (MAPK) signaling enhances CIITA activation, thereby amplifying MHC II expression and gluten antigen presentation. Emerging evidence also implicates protein kinase Cδ (PKCδ) as a key modulator of interferon gamma (IFN-γ)-driven CIITA expression and a target of tTG-mediated autoimmunity in CD. Moreover, hormonal influences, vitamin D deficiency, and gut microbiota–derived metabolites (e.g., butyrate) may fine-tune MHC II expression, contributing to sex-biased prevalence and geographic variability. Therapeutically, targeting CIITA regulatory nodes could complement gluten-free diets (GFD). By integrating genetic, epigenetic, and environmental perspectives, this review advances our understanding of CD pathogenesis. Introduction Short arm Human leukocyte antigens (HLAs), located on the 6th chromosome's short armarm of the 6th discovereinitially discovered in mice and encodes proteins that are essential mediators of immune rejection in tissue grafts between genetically diverse individuals (1). Spanning roughly 4,000 kilobases, the HLA gene complex has undergone extensive evolution through processes such as gene duplication and conversion. Within the HLA region, there are 19 expressed HLA or HLA-like genes, approximately 80 other expressed non-HLA genes, and 27 pseudogenes or gene fragments. However, the functions of most of these genes are still uncertain (2, 3). The HLA gene system is divided into two primary groups: classical and nonclassical variants. Classical HLA genes, which have been extensively studied, are primarily responsible for processing and displaying antigens to immune cells, particularly T lymphocytes. This category includes HLA class I genes (HLA-A, HLA-B, HLA-C) and class II genes (HLA-DR, HLA-DQ, HLA-DP). In contrast, nonclassical HLA genes, such as HLA-E, HLA-F, HLA-G, HLA-DM, and HLA-DO, exhibit more specialized functions and are less directly involved in conventional antigen presentation pathways (1). Specifically, HLA class I molecules display peptides derived from intracellular (endogenous) antigens to CD8+ cytotoxic T cells, activating targeted immune destruction of compromised cells. Conversely, HLA class II molecules exhibit narrower cellular expression and specialize in processing extracellular pathogens. These class II proteins bind exogenous antigens, presenting them to CD4+ helper T cells to orchestrate broader immune activities, including antibody production and inflammatory signaling (4, 5). The HLA class II genes HLA-DR and HLA-DQ are widely regarded as the most influential genetic factors contributing to the pathogenesis of many autoimmune disorders the development of celiac disease (CD) (7). HLA-DQ molecules act as receptors on antigen-presenting cells (APCs), displaying a strong affinity for deamidated gluten peptides. Upon binding these peptides, HLA-DQ presents them to CD4-positive T cells, initiating an immune response that contributes to CD pathogenesis (8, 9). Although HLA-DQ2 and HLA-DQ8 alleles represent the strongest genetic determinants of CD, genome-wide association studies (GWAS) have identified over 40 additional non-HLA loci contributing to disease susceptibility (10). These include variants in genes encoding immune regulatory molecules, such as interleukin (IL)-2, IL-21, SH2B3 (LNK), TAGAP, and CCR3, which are involved in T-cell activation, cytokine signaling, and immune tolerance (10, 11). In recent years, several studies have provided new mechanistic insights into the molecular regulation of MHC class II expression. Novel findings have identified post-translational and epigenetic regulatory layers that refine MHC II transcription in immune and epithelial cells (12-14). This review aims to comprehensively explore the multifaceted regulation of MHC class II expression in the context of CD4+ T cells. We integrate current evidence on genetic, epigenetic, and post-translational mechanisms, highlighting how environmental factors such as gluten exposure, microbial metabolites, and hormonal influences contribute to disease pathogenesis. Methods This review was conducted through a comprehensive literature search of PubMed, Scopus, and Web of Science databases for articles published between 1980 and 2025. The search terms included combinations of “celiac disease,” “MHC class II,” “HLA-DQ,” “CIITA,” “epigenetic regulation,” “post-translational modification,” and “immune response.” Additional relevant articles were identified through a manual review of the reference lists. Inclusion criteria encompassed original research articles, reviews, and experimental studies that investigated genetic, epigenetic, or molecular mechanisms regulating MHC class II expression in the context of CD or related autoimmune disorders. Exclusion criteria included non-English publications, case reports without mechanistic data, and conference abstracts. Data extraction focused on molecular pathways, regulatory interactions, and therapeutic implimodulation, specifically the modulation of MHC class II. Structure and genetic encoding of HLA-DQ molecules HLA-DQ is a receptor protein expressed on the surface of APCs and belongs to the MHC class II family as an αβ heterodimgene. The HLA-DQA1 gene produces the alpha (α) chain of HLA-DQ, while the beta (β) chain is encoded by the closely linked HLA-DQB1 gene located on chromosome 6p21.3. Now, the two allele DQA1 and DQB1 make HLA-DQ2, -DQ3, -DQ4, -DQ5, -DQ6, -DQ7, -DQ8, -DQ9 subunits. Specifically, the HLA-DQB1*02 allele group encodes the DQ2 molecule, with the most common alleles being DQB1*02:01 and DQB1*02:02. On the other hand, DQ8, a subtype within the broader DQ3 antigen group, is formed by the combination of the HLA-DQB10302 allele and the HLA-DQA1*03 allele (15). Although the existence of HLA-DQ2/8 is essential for developing CD, its presence alone is insufficient to trigger disease in most carriers (16, 17). This discrepancy underscores the need for additional regulatory mechanisms that govern HLA-DQ expression and function (16). Furthermore, post-translational modifications of HLA-DQ molecules or their interacting partners could alter antigen presentation efficiency (18). These findings have the potential to transform CD management by enabling the early identification of at-risk individuals and the development of treatments that target the regulatory mechanisms of HLA-DQ, thereby moving beyond lifelong gluten restriction as the sole therapeutic option. Chromosomes regulatory regions Certain genomic regions, commonly referred to as regulatory elements, serve as the primary regulatory components within the genome (19). These regulatory regions are distributed across chromosomes and can control gene expression through complex mechanisms, functioning from distal sites on the same chromosome or, in some cases, from different chromosomes altogether (20). Regulatory elements (REs) are classified into cis and trans genetic elements. Cis-regulatory elements are found on the same DNA molecule as the gene they regulate, while trans-regulatory elements can influence genes distant from their original transcription site (21). Critically, these gene REs are central to transcriptional regulation, coordinating essential biological processes like cell differentiation, tissue homeostasis, and potentially contributing to disease development (22). These sequences, also known as response elements, are typically categorized into promoters, enhancers, silencers, and insulators. Among these regulatory regions, core promoter elements are fundamental for initiating transcription. They serve as the platform for assembling the RNA polymerase II (Pol II) complex, along with basal transcription factors (23). Core promoter elements in gene expression RNA Pol-II transcription of protein-coding genes is a critical regulatory step in gene expression within eukaryotic cells. This process begins when the core promoter DNA is recognized, triggering the assembly of general transcription factors that together form the preinitiation complex (PIC) (21). Transcription typically starts at a specific location known as the transcription start site (TSS), located at the 5’ end of a gene, commonly referred to as the gene start. Although core promoters have the inherent ability to initiate transcription, their basal activity is typically low. This activity can be suppressed by chromatin structure or enhanced through the action of distal REs known as enhancers (24). Many core promoter sequences are widely conserved across diverse protein-coding genes and have mainly remained unchanged through evolution. Among the well-characterized canonical core promoter elements are the TDPE, and the DCE. Additionally, other element, such as MTE and XCP1, have been identified but are less frequently encountered. While the CCAAT box, found between approximately −50 bp and −80/−100 base pairs upstream of the TSS, is not typically classified as a canonical core promoter element, it exhibits conservation from bacteria to metazoans (23). The TATA box is a highly conserved core promoter element, recognized as one of the most ancient promoter sequences across diverse organisms. Based on the presence or absence of this element, eukaryotic genes are classified as either TATA-containing or TATA-less (25). Enhancer elements in gene expression Enhancers are distal Cis-regulatory elements that attract specific transcription factors and chromatin-remodeling co-factors, serving as pivotal regulators of transcription initiation at promoters. Enhancers have a crucial role in driving tissue-specific gene expression. The coordinated activity of numerous enhancers may modulate genes subject to stringent regulatory control. The coordinated activity of enhancers and promoters is crucial for regulating transcriptional programs across various cell types (26). Extensive analysis of enhancers has detected several features. First, these elements are functional over a considerable distance. Another feature of enhancers is that they are often associated with a gene that is abundantly expressed (26). Notable enhancers include the β-globin LCR, critical for erythroid-specific beta-globin expression; ZRS, a limb-specific enhancer regulating Sonic hedgehog (SHH) during limb development; HACNS1, linked to human-specific evolution in limb and brain development; super-enhancers, which orchestrate pluripotency genes like OCT4 and NANOG in stem cells; the MYC oncogene enhancer, often amplified in cancers to drive tumorigenesis; and estrogen-responsive enhancers near genes like GREB1, which mediate hormone-dependent transcription. These elements exemplify the diverse roles of enhancers in development, evolution, and disease (27). Silencer elements in gene expression Silencers are involved in regulating distantly located genes by creating interactions with promoters, thereby suppressing mRNA expression from target promoters. This adverse regulatory effect, in conjunction with the positive influence of enhancers, provides a more comprehensive understanding of how gene transcription is controlled (22). Although silencers were discovered decades ago and are recognized as essential regulators in development and disease, they have been studied far less extensively (28). Gene silencing is a fundamental mechanism that negatively controls gene expression, playing a crucial role in determining cell fate as well as controlling metabolism and gene activity throughout an organism’s lifespan (29). Additionally, some silencers are bifunctional and capable of enhancing gene expression in certain cellular contexts. This is exemplified by elements like β-globin LCR, which can act as silencers in erythroid precursors under hypoxic stress but enhance transcription in oxygen-rich environments. This challenges the traditional classification of enhancers and silencers as distinct entities (16). The H19 imprinting control region (ICR) acts as a silencer to regulate parent-specific expression of the Insulin-like growth factor 2 (IGF2) gene, ensuring genomic imprinting during embryonic development. In the immune system, the CD4 silencer element ensures proper T-cell development by repressing CD4 expression in inappropriate cell lineages. Similarly, the neuron-restrictive silencer element (NRSE) binds the REST/NRSF protein, suppressing neuronal gene expression in non-neuronal tissues and thereby preserving cellular identity (30, 31). Insulator elements in gene expression Insulators, also referred to as boundary elements, are specific DNA sequences that separate chromatin into distinct transcriptional domains. Along with other epigenetic mechanisms, they play a crucial role in maintaining the precise regulation of gene expression. They also contribute to the dynamic and structural organization of the nucleus (32). Functionally, insulators are DNA-protein complexes identified by their capacity to either prevent interactions between enhancers and promoters or to act as barriers that stop the spread of heterochromatin-associated gene silencing. Not every sequence labeled as an insulator exhibits both properties. Based on their functional impact, insulators are grouped into two types: ‘enhancer-blocking’ types, which disrupt enhancer-promoter interactions, and ‘barrier’ types, which limit the extension of heterochromatin, as observed in specific experimental contexts (33). For instance, within the H19/IGF2 ICR, the binding site for the CCCTC-binding factor (CTCF) functions as an enhancer-blocking insulator by preventing enhancers on the maternal chromosome from activating IGF2 (34). Similarly, twelve CTCF-binding sites have been identified within the HLA class II locus, where they play a structural role in organizing chromatin into extended regulatory loops that confine enhancer activity (35). MHC class II gene regulation MHC class II gene expression is regulated by a specialized enhancer complex that integrates the activity of various transcription factors and co-activators. Within the promoter region of MHC genes, several conserved cis-regulatory elements, namely the W/S-, X1-, X2-, and Y-boxes, serve as binding sites for specific transcription factors. The X1-box recruits the regulatory factor X (RFX) heterodimer complex. At the same time, the X2-box binds cyclic AMP response element-binding proteins (CREB) or a heterodimer of CREB and activating transcription factor 1 (ATF-1). The Y-box functions as the binding site for the nuclear transcription factor Y (NF-Y) complex. In contrast, no transcription factors have been identified that specifically bind to the W/S-box, leaving its regulatory role uncertain (36). The MHC class II trans-activator (CIITA) is crucial for efficient transcription of MHC class II genes (37) (Figure 1). CIITA: Master Regulator of MHC II CIITA acts as a transcriptional coactivator that initiates MHC class II gene expression by interacting with the enhanceosome complex, rather than binding directly to DNA. Serving as the master regulator of MHC class II transcription, CIITA is transcribed from three distinct promoters, pI, pIII, and pIV, each producing isoforms with cell–type–specific expression patterns. Its activity is finely tuned through multiple post-translational modifications (PTMs), including acetylation, phosphorylation, and ubiquitination (38). CIITA is widely regarded as the “master regulator” of MHC class II genes, playing an essential role in interferon (IFN)-induced MHC expression as a core component of the MHC II enhanceosome. Its constitutive expression is restricted to APCs, thereby conferring a cell-type-specific pattern of MHC class II molecule expression (33, 34). Schematic representation of the MHC class II enhanceosome complex, highlighting key components including p300 (histone acetyltransferase), PCAF (p300/CBP-associated factor), CIITA (class II major histocompatibility complex transactivator), RFX5 (regulatory factor X5), CBP (CREB-binding protein), CREB/ATF1 (cAMP response element-binding protein/activating transcription factor 1), NF-Y (nuclear transcription factor Y), RNA polymerase II (RNA Pol II), and the SXY module (W/S, X1, X2, Y). P-TEFb (positive transcription elongation factor b) facilitates transcriptional elongation. The enhanceosome orchestrates coordinated transcriptional regulation of MHC class II genes. CIITA belongs to a protein family presenting a leucine-rich repeat (LRR) domain. (39). By forming strong associations with components of TFIID, specifically TAFII32 and TAFII70, as well as with TFIIB, CIITA promotes transcription initiation (40). Additionally, CIITA contributes to chromatin remodeling through its association with CREB-binding protein (CBP) and p300/CBP-associated factor (pCAF) (41). Moreover, CIITA also supports promoter clearance and transcriptional elongation by binding to cyclin T1, a subunit of the positive transcription elongation factor b (P-TEFb) complex (42). The study by Pérez et al. (14) emphasized that CIITA promoter activation is coordinated with localized chromatin remodeling, involving H3K27 acetylation and alterations in DNA methylation (14). The recruitment of CIITA is mediated by the RFX and NF-Y transcription factor complexes, which specifically bind to conserved upstream sequences within MHC class II promoters (43). A recent study by Rane et al. (13) identified the transcription factor ZBTB48 as a chromatin-priming regulator that facilitates cell-type–specific activation of CIITA promoters, particularly pIII in professional APCs (13). CIITA modifications and its effects on CD pathogenesis The expression of CIITA is tightly controlled, with distinct promoter regions governing its baseline levels and INF-γ-mediated induction. This suggests that cytokines like IFN-γ not only directly enhance HLA expression by increasing regulatory factors, such as CIITA, but also modulate its stability (44). Beyond promoting MHC class II expression in immune cells, INFγ enhances immune activation by driving MHC class II-mediated antigen presentation in dendritic cells (DCs) (45). To prevent excessive inflammation from sustained HLA upregulation, CIITA is rapidly targeted for degradation through the ubiquitin-proteasome pathway and has a very short half-life of roughly 30 minutes. Certain viruses, including Epstein-Barr virus (EBV), exploit this regulatory mechanism by producing proteins that suppress CIITA activity, thereby inhibiting HLA class II expression as a strategy to evade immune detection (44). Recent proteomic analyses have identified FBXO11 as an E3 ubiquitin ligase that directly targets CIITA for proteasomal degradation (12). MHC class II gene regulation exemplifies the sophisticated control mechanisms governing vital immune genes, which are thoroughly explored in depth in several review articles (45). Given its importance in maintaining immune homeostasis, researchers have closely examined HLA-II expression in the context of various diseases, especially those involving immune-mediated processes (46). Its regulation is closely linked to classical epigenetic mechanisms that influence CIITA transcription (45, 47, 48). CIITA undergoes phosphorylation at multiple sites, with each modification producing distinct functional effects. For instance, phosphorylation at serine 280 has been associated with increased intracellular levels of CIITA, whereas phosphorylation at serines 286, 288, 293, 834, and 1050 has been shown to suppress its activity (46). Research has demonstrated that phosphorylation is a crucial modification for directing CIITA to the nucleus, enhancing its transactivation capability, and promoting oligomerization (46). Morgan et al. (38) demonstrated that extracellular signal-regulated kinases (ERK) 1/2 phosphorylate CIITA isoform III at Ser280, a modification that boosts CIITA’s transactivation function, elevates MHC II mRNA levels, and promotes higher MHC II surface expression (38). Furthermore, research has revealed that exposure of DCs to gliadin digest activates multiple mitogen-activated protein kinase (MAPK) pathways, leading to the phosphorylation of p38 MAPK, ERK1/2, and c-Jun N-terminal kinases (JNK) 1/2 (49). Given that gliadin is a major component of gluten and is known to trigger immune responses in susceptible individuals, its high consumption may lead to sustained activation of these pathways. This persistent signaling could enhance CIITA phosphorylation, driving prolonged upregulation of MHC II expression. Elevated MHC II levels may then contribute to increased antigen presentation, potentially exacerbating inflammatory immune responses, such as those seen in CD or gluten sensitivity (49). The protein kinase C (PKC) family, composed of serine/threonine-specific kinases, is involved in modulating MHC class II expression in response to IFN-γ stimulation. Experimental introduction of PKC into peritoneal macrophages enhances MHC class II expression, whereas the use of PKC-specific inhibitors, such as staurosporine, calphostin C, or H7, effectively suppresses this upregulation. PKCα regulates the IFN-γ-driven CIITA gene expression by controlling the transactivation capacity of interferon regulatory factor 1 (IRF-1) (50). Dysregulation of PKC activity could influence the severity of CD by altering immune activation in the gut mucosa. Analysis of PKCδ revealed a glutamine-rich motif, indicating its potential as a tissue transglutaminase (tTG) substrate, which was later confirmed by MALDI-TOF peptide analysis. Further experiments demonstrated that tTG can catalyze the transamidation of PKCδ. Notably, elevated levels of anti-PKCδ antibodies were found in patients with CD but not in those with other autoimmune conditions. These findings indicate that, in a subset of CD patients, autoimmunity against PKCδ may arise as a consequence of tTG–PKCδ interactions (51). While direct evidence linking CIITA dysregulation to reduced regulatory T-cell (Treg) number or function in active CD is limited, indirect mechanisms are plausible. CIITA-driven overexpression of HLA-DQ molecules may enhance antigen presentation and inflammatory signaling, thereby impairing peripheral tolerance and the stability of Tregs. Similar effects of aberrant CIITA or MHC class II expression on Treg homeostasis have been reported in other autoimmune diseases (38, 41, 46, 52). Prostaglandins (PGs) are lipid compounds derived from the metabolism of arachidonic acid via cyclooxygenase (COX) enzymes, which are known for their role in promoting inflammation. They enhance inflammatory responses by dilating blood vessels and increasing vascular permeability, amplifying the effects of histamine, bradykinin, and leukocyte-attracting molecules (53). These mediators also regulate the function of immune cells, particularly in macrophages. Notably, PGE subtypes suppress IFN-γ-stimulated expression of MHC class II in macrophages, demonstrating their immunomodulatory potential (54). PGE receptors activate adenyl cyclase, resulting in elevated production of intracellular cyclic AMP (cAMP) levels, which can activate protein kinase A (PKA). Treatment with PGE, which elevates intracellular cAMP levels, induces a transcription-dependent decrease in MHC class II surface expression. In summary, treatment with PGs and cAMP in macrophages inhibits IFN-γ-induced class II MHC gene expression. This suppression is driven by CIITA phosphorylation, with serine residues S874 and/or S1050 identified as key targets of the kinase (32). Experiments using PGE2, as a PKA activator (8-bromo-cAMP), or direct PKA transfection reduced CIITA activity in human and mouse immune cells, independent of other promoter-binding transcription factors. Mutational and biochemical analyses identified two key serine residues (S834 and S1050) in CIITA as sites of PKA phosphorylation, responsible for blocking MHC class II gene activation (55). Gliadin peptides have been shown to increase COX-2 expression, leading to increased PGE2 production. Paradoxically, CD patients exhibit MHC II overexpression, likely due to compartmentalized effects: lamina propria PGE2 drives fluid secretion and diarrhea, while IFN-γ dominates in epithelia, sustaining CIITA activity. Chronic inflammation may also desensitize PGE2 receptors, impairing cAMP-mediated suppression. Therapeutically, targeting PGE2 pathways could modulate MHC II expression, but this approach risks disrupting mucosal protection, highlighting the complex interplay between PGE2’s pro-inflammatory and immunoregulatory roles in CD pathogenesis (56, 57). Histone acetylation is a key regulatory mechanism controlling the gene expression of MHC II. Upon IFN-γ stimulation, histone H4 acetylation coincides with RNA Pol-II recruitment before transcription begins, while histone H3 acetylation increases during active mRNA synthesis and relies on RNA Pol-II elongation. CIITA interacts with several histone acetyltransferases (HATs), including CBP/p300, PCAF, GCN5, and other HATs such as steroid receptor coactivator 1 (SRC1) (58, 59). Remarkably, CIITA itself exhibits HAT activity, providing a possible mechanism through which hormones like estrogens and glucocorticoids can modulate the gene expression of MHC II (35). In CD, this hormonal influence may contribute to the sex-biased prevalence (higher in women) (60). CIITA-HAT interactions could enhance presenting gluten peptides to CD4+ T cells, exacerbating inflammation. Additionally, glucocorticoids, often used to treat refractory CD, might paradoxically suppress MHC class II via this pathway, suggesting a therapeutic avenue (61). Acetylation of lysines K141 and K144 on CIITA, mediated by CREB and the acetyltransferase PCAF, can enhance CIITA’s nuclear accumulation and its ability to activate MHC class II gene transcription (36). Butyrate is a short-chain fatty acid generated by gut microbiota, exhibiting dual and context-dependent effects on immune regulation and MHC class II expression in CD. It can function as a histone deacetylase (HDAC) inhibitor, increasing global histone acetylation, including at the CIITA promoter regions, which potentially amplifies CIITA-driven MHC-II expression in APCs (62). Paradoxically, butyrate can downregulate MHC II in activated immune cells (e.g., mature DCs) through GPR109A/GPR43 signaling, which suppresses nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and signal transducer and activator of transcription 1 (STAT1) pathways (63). In CD, butyrate has been demonstrated to enhance intestinal epithelial barrier integrity by reducing permeability, boosting mucus secretion, and alleviating inflammation caused by bacterial translocation (64). Reports indicate that administering low, non-toxic doses of butyrate reduced the surface expression of MHC class II molecules on mature DCs (64). In infants, intestinal butyrate production follows a defined developmental trajectory, with concentrations increasing fourfold between 6 and 12 months to reach maternal levels, paralleling the colonization of butyrate-producing bacteria, such as Faecalibacterium prausnitzii and Eubacterium rectale. This microbial transition is critical for immune programming, as evidenced by dysbiosis in CD featuring reduced butyrogenic species and Bifidobacteria (65). Therapeutic strategies leveraging butyrate (e.g., dietary supplementation, microbiota modulation) could thus target both mucosal healing and immune dysregulation, though further research is necessary to fully understand how butyrate influences CIITA acetylation and antigen presentation in individuals with CD (66). Vitamin D has been recognized for its immunomodulatory properties, with early research sug; however, the precise mechanisms remain unclear (67). The primary source of vitamin D in humans is through synthesis via ultraviolet (UV) radiation-dependent metabolism. However, at higher latitudes, limited solar exposure, especially during winter months, results in insufficient vitamin D production. As a result, low vitamin D levels have been linked to an increased susceptibility to various autoimmune and infectious diseases. Vitamin D deficiency, common in high-latitude regions with limited sunlight, may exacerbate the risk of CD by dysregulating immune tolerance. Epidemiological studies suggest a higher prevalence of CD in northern climates, possibly due to low vitamin D levels impairing T-cell regulation and promoting inflammatory responses to gluten (68, 69). Thus, insufficient vitamin D levels may contribute to CD pathogenesis by altering MHC class II-dependent immune activation, underscoring its possible influence on disease susceptibility and severity. Therapeutic prospects of targeting the MHC class II enhanceosome Given its central role in antigen presentation and immune activation, aberrant or sustained enhanceosome activity has been implicated in mucosal inflammation and autoimmunity. Recent research has explored strategies to selectively modulate this complex, aiming to normalize MHC II expression rather than abolish it entirely. HDAC inhibitors have garnered particular attention due to their ability to remodel chromatin accessibility at the CIITA promoter and associated enhancer regions. Low-dose pan-HDAC inhibitors such as vorinostat (SAHA) and trichostatin A have been shown in preclinical studies to suppress IFN-γ–induced MHC II expression in APCs by altering histone acetylation dynamics and limiting CIITA recruitment (70, 71). Similarly, selective HDAC3 inhibition in intestinal epithelial models restored barrier integrity and attenuated inflammatory cytokine production, suggesting that controlled modulation of histone acetylation may have therapeutic benefit without broad immunosuppression (72). Small molecules or peptides designed to interfere with CIITA’s interaction with the RFX–NF-Y enhanceosome have demonstrated proof-of-concept in reducing class II transcription in DCs (73). Moreover, targeting upstream kinases, such as PKCδ or ERK1/2, that post-translationally activate CIITA offers an alternative route to dampen pathological MHC II overexpression (74). However, any therap, and strike a balance between effectiveness and the conservation of essential antigen presentation necessary for immune competence. Future study employing intestinal organoids, mucosal explants, and humanized mouse models will be critical to evaluate the safety, specificity, and reversibility of MHC II-directed interventions. These evidences highlight the intricate interplay of genetic susceptibility, environmental elements, and immune dysfunction that collectively disrupt intestinal homeostasis in CD. Future studies should aim to clarify the specific mechanisms through which CIITA and its regulatory pathways are altered in CD, with particular attention to cases that are non-responsive or refractory to treatment. Targeting these pathways could offer novel therapeutic strategies beyond gluten restriction. Additionally, investigating the sex-biased prevalence and hormonal influences on MHC class II expression may uncover personalized approaches for disease management. By dissecting the interplay between genetic, epigenetic, and environmental factors, we can move closer to precision medicine for CD, improving diagnostics, treatment, and long-term outcomes for patients worldwide. Given the involvement of these complexes and potentially other factors in modifying chromatin structure and activating transcription, two key questions arise. First, do these events occur exclusively at MHC II genes? Second, how are these activities spatiotemporally coordinated at MHC II promoters? Further research is needed to elucidate whether these regulatory principles extend to other immunologically relevant genes and how their dysregulation contributes to autoimmune pathogenesis, including CD. Conclusion These insights not only refine our comprehension of disease mechanisms but also open new avenues for therapeutic intervention. Moving beyond lifelong gluten avoidance, future strategies may target specific nodes in the MHC class II regulatory cascade, such as CIITA activity, PKCδ signaling, or supplementation with microbial metabolites. Additionally, the observed sex disparities and latitude-dependent prevalence patterns suggest opportunities for personalized prevention and management approaches. As research continues to unravel the multifaceted nature of CD, integrating genetic, epigenetic, and ecological perspectives will be essential for developing more effective diagnostics and treatments, ultimately improving the well-being of affected individuals worldwide.